Degarelix

DB06699ApprovedInvestigationalSmall moleculeGonadotropin-releasing Hormone Antagonists

Degarelix is a GnRH receptor antagonist used in the management of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH.

Mechanism: Degarelix competitively inhibits GnRH receptors in the pituitary gland, preventing the release of luteinizing hormone (LH) and follicle stimulating hormone. Reduced LH suppresses testosterone release, which slows the growth and reduces the size of prostate cancers.
Curator reviewed
Primary indication: In Canada and the US, degarelix is indicated for the treatment of advanced prostate cancer in patients requiring androgen deprivation therapy.Curator reviewed · 4 structured indications
Formula / weight: C₈₂H₁₀₃ClN₁₈O₁₆ · 1632.29 g/mol (avg)
First approval: Canada, 2009 · United States, 2009 · European Union, 2016
Code names: ASP-3550 · FE-200486
Brand names: Degarelix Accord
Firmagon

Resolves to

Compound

UNIISX0XJI3A11CAS214766-78-6ChEMBLCHEMBL415606ChEBI135961PubChem16136245KEGGD08901

Clinical / RWD

RxNorm475230ATCL02BX02PharmGKBPA165958373

Structure

InChIKeyMEUCPCLKGZSHTA-XYAYPHGZSA-NSMILES

CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC1=CC=C(NC(=O)[C@@H]2CC(=O)NC(=O)N2)C=C1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC1=CC=CN=C1)NC(=O)[C@@H](CC1=CC=C(Cl)C=C1)NC(=O)[C@@H](CC1=CC=C2C=CC=CC2=C1)NC(C)=O)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O

Targets

P30968GNRHR

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

427Drug interactionsStructured to mechanism, not free text

105Clinical trialsPhase, status and sponsor resolved per trial

4Structured indicationsCondition, population, route and combination as fields, not prose

1ContraindicationEach with its own population and attribute set

26Marketed productsAcross 8 countries and 4 labellers

1ATC codeIncluding every combination product, plus 13 drug categories

13+ReferencesStructured and connected to the statements they support

Which drugs share a target with Degarelix, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account